BiVictriX AIM Rule 17 Notice

RNS Number : 1999J

BiVictriX Therapeutics PLC

25 April 2022

 

BIVICTRIX THERAPEUTICS PLC

("BiVictriX" or "the Company" or "the Group")

AIM Rule 17 Notice

Alderley Park, 25 April 2022 - BiVictriX Therapeutics plc (AIM: BVX), an emerging biotechnology company applying a novel approach to develop next generation cancer therapies using insights derived from frontline clinical experience, announces that Iain Ross, Chairman of BiVictriX, has advised the Company that further to the announcement of 17 December 2021 regarding Palla Pharma Limited ("Palla Pharma"), of which he was a Non-Executive Director, entering into voluntary administration, Palla Pharma has entered into liquidation.  Iain Ross's resignation from the board of Palla Pharma was accepted on 20 April 2022.

This announcement is made pursuant to Rule 17 and schedule 2, paragraph (g) of the AIM Rules for Companies.

-Ends-

For more information, please contact:

BiVictriX Therapeutics plc
Tiffany Thorn, Chief Executive Officer Iain Ross, Chairman	Email: [e-mail]
SP Angel Corporate Finance LLP (NOMAD and Broker)	Tel: [phone]
David Hignell, Caroline Rowe (Corporate Finance) Vadim Alexandre, Rob Rees (Sales and Broking) Panmure Gordon (UK) Limited (Joint Broker) Rupert Dearden, Freddy Crossley, Emma Earl	Tel: [phone]
Consilium Strategic Communications
Mary-Jane Elliott, Melissa Gardiner, Genevieve Wilson	Tel: [phone] Email: [e-mail]

About BiVictriX Therapeutics plc

BiVictriX is a UK-based drug discovery and development company which is focused on leveraging clinical experience to develop a class of highly selective, next generation cancer therapeutics which exhibit superior potency, whilst eliminating treatment-related toxicities.

The Company utilises a first-in-class approach to generate a proprietary pipeline of Bi-Cygni® therapeutics which are designed to selectively target antigen co-expression fingerprints, or "twin antigens", on tumour cells, which are largely absent from healthy cells. Whereas this concept has been validated in a clinical diagnostic setting to support the diagnosis and monitoring of haematological cancers, it has not yet been widely used in a therapeutic setting.

BiVictriX has identified a diverse panel of novel cancer-specific "twin antigens", across a broad range of solid tumour and haematological cancer indications. The Company is using these novel "twin-antigens" to develop more effective and safer therapeutics to target cancers that are expected to constitute orphan indications and currently constitute areas of high unmet medical need.

Find out more about BiVictriX online at www.bivictrix.com  

 

END

 

 

MSCPPUMPCUPPURA